In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody

Blood

Volumn 103, Issue 7, 2004, Pages 2617-2623

  Gilles, Jean Guy G ^a   Grailly, Sabrina C ^b   De Maeyer, Marc ^b   Jacquemin, Marc G ^b   VanderElst, Luc P ^b   Saint Remy, Jean Marie R ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; IDIOTYPIC ANTIBODY; LEUCINE; METHIONINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B14C12; MONOCLONAL ANTIBODY BO2C11; NEUTRALIZING ANTIBODY; PHENYLALANINE; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD CLOTTING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; HEMOPHILIA A; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; THREE DIMENSIONAL IMAGING;

EID: 1642324071     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2207     Document Type: Article

References (35)

1. Briët E, Rosendaal FR, Kreuz W. A meta-analysis based on eight long-term followup studies concerning inhibitors associated with crude or intermediate purity FVIII products. Throm Haemost. 1994;72:162-164.
2. Ehrenforth S, Kreuz W, Sharrer I, et al. Incidence of FVIII and FIX inhibitors in hemophiliacs [letter]. Lancet. 1992;339:594.
3. Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol. 2001;38(suppl 12):43-47.
4. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost. 2003;29:69-76.
5. Ware J, MacDonald M, Lo M, de Graaf S, Fulcher C. Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide. Blood Coagul Fibrinolysis. 1992;3:703-716.
6. Hoyer L, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol. 1994;31(2 Suppl 4):1-5.
7. Jacquemin M, Desqueper B, Benhida A, et al. Mechanisms and kinetics of FVIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood. 1998;92:496-501.
8. Spiegel P, Jacquemin M, Saint-Remy JM, Stoddard B, Pratt K. Structure of FVIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of FVIII. Blood. 2001;98:13-19.
9. Algiman M, Dietrich G, Nydegger U, Boeildieu D, Sultan Y, Kazatchkine M. Natural antibodies to FVIII (anti-haemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A. 1992;89:3795-3799.
10. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic. J Clin Invest. 1994;94:1496-1505.
11. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest. 1996;97:1382-1388.
12. Pascual V, Capra J. Tolerance to factor VIII inhibitors in hemophilia a patients: a French twist. J Clin Invest. 1996;97:1357-1358.
13. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-FVIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotopic restriction. Blood. 1993;82:2452-2461.
14. van den Brink E, Bril W, Turenhout E, et al. Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. Blood. 2002;99:2828-2834.
15. Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 2000;95:156-163.
16. Chothia C, Lesk AM, Tramontano A, et al. Conformations of immunoglobulin hypervariable regions. Nature. 1989;342:877-883.
17. Kabsch W, Sander C. How good are predictions of protein secondary structure? FEBS Lett. 1983;155:179-182.
18. Myers E, Miller W. Optimal alignments in linear space. Comput Appl Biosci. 1988;4:11-17.
19. Pratt K, Shen B, Takeshima K, Davie E, Fujikawa K, Stoddard B. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature. 1999;402:439-442.
20. Villard S, Piquer D, Raut S, Leonetti JP, Saint-Remy JM, Granier C. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem. 2002;277:232-239.
21. Singh I, Smith A, Vanzieleghem B, et al. Anti-thrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood. 2002;99:3235-3240.
22. d'Oiron R, Lavergne J.-M., Lavend'homme R, et al. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood. 2004;103:155-157.
23. Saenko E, Yakhyaev A, Mikhailenko I, Strickland D, Sarafanov A. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem. 1999;274:37685-37692.
24. Lenting P, Neels J, van den Berg B, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999;274:23734-23739.
25. Hudson P, Souriau C. Engineered antibodies. Nat Med. 2003;9:129-134.
26. Fuentes-Prior P, Fujikawa K, Pratt K. New insights into the binding interfaces of coagulation factors V and VIII and their homologues: lessons from high resolution crystal structures. Curr Protein Pept Sci. 2002;3:313-339.
27. Fulcher C, de Graaf Mahoney S, Zimmerman T. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood. 1987;69:1475-1480.
28. Scandella DH, Nakai H, Felch M, et al. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Thromb Res. 2001;101:377-385.
29. Voorberg J, van den Brink EN. Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII. Semin Thromb Hemost. 2000;26:143-150.
30. Hay C, Colvin B, Ludlam CA, Hill F, Preston F. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coagul Fibrinolysis. 1996;7:134-138.
31. McHeyzer-Williams MG. B cells as effectors. Curr Opin Immunol. 2003;15:354-361.
32. Timmerman J, Debra K, Czerwinski D, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
33. Vuist W, Levy R, Maloney D. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood. 1994;83:899-906.
34. Benhamou L, Cazenave P, Sarthou P. Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol. 1990;20:1405-1407.
35. Sulica A, Morel P, Metes D, Herberman R. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol. 2001;20:371-414.